Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects
- PMID: 2804986
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects
Abstract
Because recombinant interleukin 2 (rIL-2) and recombinant alpha-interferon (rIFN-alpha) exhibit synergistic antitumor activity in C3HMT1820 T-cell lymphoma and B16 melanoma tumor systems, we have performed a Phase I study of this combination in 55 patients with advanced malignancies for whom no standard therapy exists. Successive groups of greater than or equal to 4 patients have been entered into 12 dose levels (1A-3D), with dose levels 1-3 referring to doses of rIL-2 of 0.1, 0.5, and 2.0 x 10(6) units/m2, respectively, and dose levels A-D referring to doses of recombinant human alpha 2a-interferon (rHuIFN-alpha 2a) of 0, 0.1, 1.0, and 10.0 x 10(6) units/m2. Both agents were given on Mondays, Wednesdays, and Fridays, with rIL-2 being given as i.v. bolus injections and rHuIFN-alpha 2a being given intramuscularly. Myelosuppression was dose-limiting and was related primarily to the dose of rHuIFN-alpha 2a. The maximum-tolerated dose level was reached at a dose of rIL-2 of 2.0 x 10(6) units/m2 and of rHuIFN-alpha 2a of 10.0 x 10(6) units/m2 (dose level 3D). At this dose level, 3/6 patients developed grade 3 neutropenia (absolute granulocyte count less than 1 x 10(9)/liter). Myelosuppression was transient, with no documented infections being associated with neutropenia. Hypotension was mild; a single patient was treated with a vasopressor, but all other cases of hypotension responded to fluid administration. No significant pulmonary toxicity was produced. Fever, chills, and malaise were universal but not dose-limiting. Three partial responses and one minor response were observed in patients with malignant melanoma, renal cell carcinoma, and breast cancer. Immunological studies suggested that natural killer activity was related to both the dose of rIL-2 and the dose of rHuIFN-alpha 2a, with natural killer activity being positively related to the dose of rIL-2 and maximal at the lowest dose of rHuIFN-alpha 2a of 0.1 x 10(6) units/m2.
Similar articles
-
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.J Clin Oncol. 1992 May;10(5):804-9. doi: 10.1200/JCO.1992.10.5.804. J Clin Oncol. 1992. PMID: 1569452 Clinical Trial.
-
Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.Clin Cancer Res. 2000 Apr;6(4):1267-72. Clin Cancer Res. 2000. PMID: 10778950 Clinical Trial.
-
Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.J Biol Response Mod. 1989 Oct;8(5):468-78. J Biol Response Mod. 1989. PMID: 2795092
-
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Cancer J Sci Am. 1997. PMID: 9457399 Review.
-
The role of interleukin-2 in the biotherapy of cancer.Oncol Nurs Forum. 1989 Nov-Dec;16(6 Suppl):16-20. Oncol Nurs Forum. 1989. PMID: 2687810 Review.
Cited by
-
Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.Med Oncol. 1995 Jun;12(2):69-77. doi: 10.1007/BF01676706. Med Oncol. 1995. PMID: 8535664
-
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.Br J Cancer. 1995 Jun;71(6):1319-21. doi: 10.1038/bjc.1995.256. Br J Cancer. 1995. PMID: 7779731 Free PMC article. Clinical Trial.
-
Cytokine combinations in immunotherapy for solid tumors: a review.Cancer Immunol Immunother. 1993 Sep;37(4):213-9. doi: 10.1007/BF01518513. Cancer Immunol Immunother. 1993. PMID: 8348559 Free PMC article. Review.
-
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).Invest New Drugs. 2004 Jan;22(1):83-9. doi: 10.1023/b:drug.0000006178.32718.22. Invest New Drugs. 2004. PMID: 14707498 Clinical Trial.
-
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.J Cancer Res Clin Oncol. 1993;119(12):745-55. doi: 10.1007/BF01195347. J Cancer Res Clin Oncol. 1993. PMID: 8408187 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical